Release date: 2017-01-17 Recently, Israeli biotechnology company Neuronix announced its positive results in a critical clinical trial of neuroAD, a treatment system for Alzheimer's disease. In patients with moderate Alzheimer's disease, the neuroAD therapeutic device significantly improved the patient's cognitive ability. Alzheimer's disease is one of the most common neurological diseases leading to a decline in memory and cognitive abilities in the elderly, with more than 40 million patients worldwide and nearly 10 million patients in China. At present, there is no effective treatment for the disease, and only a limited number of drugs can alleviate the symptoms. Due to the high incidence of Alzheimer's disease and long duration of disease, it often brings a large economic burden to the family and society of patients. The neuroAD treatment system developed by Neuronix is ​​a new type of non-invasive therapeutic device. It combines two existing treatments, cognitive training and Transcranial Magnetic Stimulation (TMS), to design a targeted cognitive training program based on the actual situation of each patient, while stimulating disease-affected Brain area to improve the condition. The device can also be used with existing drugs to achieve optimal therapeutic results. neuroAD treatment instrument (Source: medscape) In this randomized, double-blind, controlled clinical trial, a total of 131 patients with Alzheimer's disease from the United States and Israel participated. Each patient received a 6-week treatment and was followed up 6 weeks after the end of treatment. The cognitive ability of the patients was assessed by both ADAS-Cog and CGI-C tests. At 12 weeks, among the moderate patients who accounted for 85% of the entire trial participants, patients who received neuroAD treatment had a 1.8-point improvement in the ADAS-Cog test compared to the control group, achieving statistical significance. Sex. In the CGI-C test, all treated patients had a 0.4-point improvement compared to the control group, with moderate patients having a 0.45-point improvement. Only 16% of the patients who received treatment experienced cognitive decline, compared with 42% of the control group who had a regression. In addition, there were no serious side effects in the patients, and most patients completed the entire course of treatment. Mr. Eyal Baror, CEO of Neuronix, said: "We are proud to present data from this critical clinical trial. This trial was performed at some of the most experienced Alzheimer's Disease Research Centers in the United States. We thank all The people involved in the trial, especially the patients and their families. For them, we will do our utmost to get the neuroAD therapeutic device approved in the US and globally." Mr. Eyal Baror, CEO of Neuronix (Source: reuters) Based on positive data from this trial and other trials conducted previously, Neuronix has submitted an application for a new medical device to the US FDA and is eligible for a rapid approval channel. The system has been approved for use in Europe earlier. We hope that the neuroAD therapeutic device will benefit more patients around the world at an early date. Source: WuXi PharmaTech Infusion Set,precise infusion set,light resistant infusion set Shandong Zhushi Pharmaceutical Group Co.,LTD , https://www.sdzs-medical.com